Dexmedetomidine, Midazolam

ApprovedSmall molecule

Dexmedetomidine, Midazolam is one of 37 small molecule programs targeting Supraventricular tachycardia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Supraventricular TachycardiaActive, not recruiting

Oxidative StressActive, not recruiting

Supraventricular TachycardiaPreclinical

Active, not recruiting

Oxidative StressApproved

Active, not recruiting

Competition

Competitive Landscape

138 competitors in Oxidative Stress

#DrugCompanyPhaseTrials

Kerendia

Bayer

Phase 3

1 2

Qvar

SSchering-Plough

Phase 3

1 3

Droxia

TTheravia

Phase 3

1 4

Ascorbate

FFudan University

Phase 3

1 5

Dexmedetomidine, Midazolam

NNational Taiwan University Hospital

Approved

1 6

Niacin/laropiprant

Merck & Co.

Phase 3

1 7

Pterostilbene

UUniversity of Mississippi Medical Center

Phase 3

1 8

Bayer Aspirin

Bayer

Preclinical

1 9

Nicorette

Pfizer

Preclinical

1 10

Tractocile

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oxidative Stress1 trial

Comparing the Effect of Dexmedetomidine With Midazolam on Sedation, Oxidative Stress, and Microcirculation in Intensive Care Unit

Completed·NNational Taiwan University Hospital·Phase 4·NCT00886275·33 enrolled

Supraventricular tachycardia1 trial

Treatment of Supraventricular Tachycardia in Patients With Non-cardiac Surgery by Dexmedetomidine

Unknown status·—·N/A·NCT04284150·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Dexmedetomidine, Midazolam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dexmedetomidine, Midazolam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dexmedetomidine, Midazolam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Taiwan University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational Taiwan University Hospital

Dexmedetomidine, Midazolam

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oxidative Stress1 trial

Supraventricular tachycardia1 trial

References

Drug Info

Quick Facts

Related News